Investor Firms Urge Baxter Shareholders to Act Before Dec. 15 in Novum IQ Pump Securities Case
Plaintiffs contend Baxter concealed serious defects in its Novum IQ infusion pump that later drew an FDA Class I recall.
Overview
- Rosen Law Firm and Glancy Prongay & Murray issued new notices reminding investors of a December 15, 2025 deadline to seek lead-plaintiff status.
- The putative class period cited in these notices spans February 23, 2022 through July 30, 2025 for purchasers of Baxter common stock.
- Filings claim the Novum IQ Large Volume Pump had systemic defects causing underinfusion, overinfusion, and non-delivery of fluids, creating risks of severe harm.
- Baxter disclosed risks in April 24 and July 14, 2025 customer letters, reporting 79 serious-injury events and two deaths, and the FDA later deemed the issue a Class I recall.
- After Baxter paused Novum IQ shipments and installations on July 31, 2025, its shares fell 22.4% to $21.61, and no class has yet been certified, allowing investors to choose counsel or remain absent class members.